A practical reference on freeze-thaw cycling: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-09. Anything still debated is marked as such rather than presented as settled.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Chemical synthesis of proteins is a valuable tool in chemical biology as it allows for the introduction of non-natural amino acids as well as residue-specific incorporation of "posttranslational modifications" such as phosphorylation, glycosylation, acetylation, and even ubiquitination. These properties are valuable for chemical biologists as non-natural amino acids can be used to probe and alter the functionality of proteins, while post-translational modifications are widely known to regulate the structure and activity of proteins. Although strictly biological techniques have been developed to achieve these ends, the chemical synthesis of peptides often has a lower technical and practical barrier to obtaining small amounts of the desired protein. To make protein-sized polypeptide chains with the small peptide fragments made by synthesis, chemical biologists can use the process of native chemical ligation. Native chemical ligation involves the coupling of a C-terminal thioester and an N-terminal cysteine residue, ultimately resulting in formation of a "native" amide bond. Other strategies that have been used for the ligation of peptide fragments using the acyl transfer chemistry first introduced with native chemical ligation include expressed protein ligation, sulfurization/desulfurization techniques, and use of removable thiol auxiliaries.
A 2017 study estimated the top running speed of Tyrannosaurus as 17 mph (27 km/h), speculating that Tyrannosaurus exhausted its energy reserves long before reaching top speed, resulting in a parabola-like relationship between size and speed. Another 2017 study hypothesized that an adult Tyrannosaurus was incapable of running due to high skeletal loads. Using a calculated weight estimate of 7 tons, the model showed that speeds above 11 mph (18 km/h) would have probably shattered the leg bones of Tyrannosaurus. The finding may mean that running was also not possible for other giant theropod dinosaurs like Giganotosaurus, Mapusaurus and Acrocanthosaurus. However, studies by Eric Snively and colleagues, published in 2019 indicate that Tyrannosaurus and other tyrannosaurids were more maneuverable than allosauroids and other theropods of comparable size due to low rotational inertia compared to their body mass combined with large leg muscles. As a result, it is hypothesized that Tyrannosaurus was capable of making relatively quick turns and could likely pivot its body more quickly when close to its prey, or that while turning, the theropod could "pirouette" on a single planted foot while the alternating leg was held out in a suspended swing during a pursuit. The results of this study potentially could shed light on how agility could have contributed to the success of tyrannosaurid evolution. In 2026, Boeye and colleagues analyzed the foot biomechanics of T. rex and determined that its foot likely functioned similarly to modern birds.
==== Excretion of HMB-Ca ==== HMB is eliminated via the kidneys, with roughly 10–40% of an ingested dose being excreted unchanged in urine. The remaining 60–90% of the dose is retained in tissues or excreted as HMB metabolites. The fraction of a given dose of HMB that is excreted unchanged in urine increases with the dose.
However, it increases serious heart problems by an absolute risk of 2.1%, though the problems may resolve if treatment is stopped. Trastuzumab has had a "major impact in the treatment of HER2-positive metastatic breast cancer." The combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to trastuzumab alone. It is possible to determine the "erbB2 status" of a tumor, which can be used to predict efficacy of treatment with trastuzumab. If it is determined that a tumor is overexpressing the erbB2 oncogene and the patient has no significant pre-existing heart disease, then a patient is eligible for treatment with trastuzumab. It is surprising that although trastuzumab has great affinity for HER2 and high doses can be administered (because of its low toxicity), 70% of HER2+ patients do not respond to treatment. In fact resistance to the treatment develops rapidly, in virtually all patients. A mechanism of resistance involves failure to downregulate p27Kip1 as well as suppressing p27 translocation to the nucleus in breast cancer, enabling cdk2 to induce cell proliferation. In May 2021, the FDA approved pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of people with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Sources: en.wikipedia.org
The sponsor and the local site investigators are jointly responsible for writing a site-specific informed consent that accurately informs the potential subjects of the true risks and potential benefits of participating in the study, while at the same time presenting the material as briefly as possible and in ordinary language. FDA regulations state that participating in clinical trials is voluntary, with the subject having the right not to participate or to end participation at any time.
== Indications == There are no clinical guidelines outlining the use and implementation of opioid rotation. However, this strategy is commonly used for these various situations: pain not controlled by current opioid, pain controlled but in the presence of intolerable adverse events, pain not controlled despite rapid increase in opioid dose, switching to utilize different alternative routes of administration, or switching due to high cost of current opioid (or other patient-specific cost considerations).
In June 2020, the Serum Institute of India (SII) – a major manufacturer of global vaccines – reached a licensing agreement with AstraZeneca to make 1 billion doses of vaccine for low-and-middle income countries, of which half of the doses would go to India. Similar preferential homeland distribution may exist if a vaccine is manufactured in Australia.
Sources: en.wikipedia.org
There are many bacteria of health significance found in indoor air and on indoor surfaces. The role of microbes in the indoor environment is increasingly studied using modern gene-based analysis of environmental samples. Currently, efforts are under way to link microbial ecologists and indoor air scientists to forge new methods for analysis and to better interpret the results. A large fraction of the bacteria found in indoor air and dust are shed from humans. Among the most important bacteria known to occur in indoor air are Mycobacterium tuberculosis, Staphylococcus aureus, Streptococcus pneumoniae.
==== On the culture of secrecy ==== David Bandurski, journalist and researcher at China Media Project, criticised the state's control of the media for suppressing "information critical to the well-being of ordinary Chinese". He asserted that increased press freedom needs to be a component of any strategy to deal with this and other future food-security lapses in China. Bandurski cited warnings on 9 October 2008 issues of Nanfang Daily and the Information Times for consumers to be aware of that problematic dairy stock (that produced before 14 September) have reappeared in some stores under cover of aggressive promotions. Former senior party official Bao Tong said "the more dark secrets are exposed, the better. You can't cure the disease, or save the Chinese people, until you get to the root of the problem." "If the Chinese government tries to play down this incident, there will be no social stability in China, let alone harmony ... It will mean that this government has lost the most basic level of trust."
== Amateur career == Helton attended Central High School in Knoxville, Tennessee and was a letterman in football and baseball. In football, he posted 2,772 total yards as a quarterback. In baseball, as a senior, Helton had a .655 batting average and 12 home runs and was named the Regional Player of the Year. Baseball America named him an All-American his senior season. He was named the Gatorade Player of the Year for football and baseball in Tennessee. Helton was drafted in the second round (55th overall) by the San Diego Padres in the 1992 MLB draft. He did not sign, instead choosing to attend college.
According to an Afghan media outlet, Pakistani aircraft have repeatedly patrolled Afghan airspace over the past two months, promoting Taliban forces to fire at them, which in some cases has resulted in casualties and damage to Afghan civilians. Two TTP militants and a policeman were killed in a clash in Lakki Marwat. On 21 April, Pakistani military claimed to have carried out an operation in Khyber District killing 22 TTP militants while a child was also killed in the crossfire. On 22 April, local Afghan sources reported that Pakistani forces carried out mortar strikes targeting Asadabad, provincial capital of Kunar province. Earlier, local Afghan sources said that the villages of Kochi, Shahbaz and Koremar in Kunar province were targeted by artillery strikes carried out by Pakistani forces. Elsewhere, border areas of Paktika province were also subjected to cross border shelling by Pakistani forces, according to local Afghan sources. No casualties were reported in these attacks, and Taliban officials did not comment on them. On 24 April, TTP attacked a police station in Dera Ismail Khan District using heavy weapons damaging the station and nearby buildings. On 26 April, three civilians were wounded in a Taliban artillery attack at Zalulkhel area in South Waziristan. In response, Pakistan claimed to have destroyed Taliban firing positions and foiled infiltration attempts. On 27 April, seven people were killed and 85 others were injured in Pakistani strikes in Kunar province, including a strike on the Sayed Jamaluddin Afghani University in the provincial capital of Asadabad.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.